LAB — Standard BioTools Share News
0.000.00%
Last trade - 00:00- $258.47m
- -$217.95m
- $85.33m
Standard BioTools Inc reports results for the quarter ended in June - Earnings Summary
Standard BioTools Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Standard Biotools Reports First Quarter 2023 Financial Results
Brief: Standard BioTools Currently Holds About $334,000 In Cash Deposits At Silicon Valley Bank
Brief: Standard Biotools Reports Fourth Quarter Results And Provides 2023 Business Outlook
Brief: Standard Biotools Expects To Reach Positive Free Cash Flow by Q4, 2024
Standard BioTools up on $20 mln share repurchase program
Brief: Standard Biotools Announces Third Quarter 2022 Financial Results
Brief: Standard Biotools And Visiopharm Announce Partnership
Brief: Ascendas Genomics Receives Nmpa Approval For Use Of Standard Biotools Microfluidics Technology To Advance The Development Of Molecular Diagnostics In China
Brief: Standard Biotools Inc - Announced A Restructuring Plan, Including A Reduction In Force
Brief: Standard BioTools Reports Qtrly Loss Per Share $0.82
Brief: Standard Biotools Inc Files For Stock Shelf Of Up To 75.2 Million Shares
Brief: Fluidigm Completes $250 Million Strategic Capital Infusion And Changes Name To Standard Biotools Inc
Brief: Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
Brief: Fluidigm Announces Support Deal With Caligan Partners
Brief: Fluidigm Urges Stockholders To Vote 'For' Proposals At Special Meeting
Brief: Fluidigm Corp Highlights The Strategic Capital Infusion By Casdin Capital And Viking Global As The Only Actionable Financing Solution
Brief: Fluidigm Corp Urges Stockholders To Vote “For” All Proposals Related To $250 Mln Strategic Capital Infusion